- Home
- CURR vs CGTX Comparison
CURR vs CGTX Comparison
Compare CURR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURR | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CURR | CGTX |
|---|---|---|
| Price | $2.08 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $3.50 | $3.33 |
| AVG Volume (30 Days) | 203.9K | ★ 848.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.22 |
| 52 Week High | $4.68 | $3.83 |
Technical Indicators
Market Signals| Indicator | CURR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 37.75 |
| Support Level | $1.47 | $0.98 |
| Resistance Level | $2.34 | $1.04 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 74.69 | 23.91 |
Price Performance
Historical ComparisonAbout CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.